Your browser doesn't support javascript.
loading
Nerve growth factor serum levels in treatment-resistant schizophrenic patients following electroconvulsive therapy.
Pacitti, F; Bersani, G; Aloe, L; Caredda, M; Orsi, P; Quartini, A; Vitali, M; Ceccanti, M; Tirassa, P; Fiore, M; Iannitelli, A.
Afiliación
  • Pacitti F; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila.
  • Bersani G; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome.
  • Aloe L; Fondazione IRET, Tecnopolo di Bologna - sede di Ozzano (BO).
  • Caredda M; Department of Neurology and Psychiatry, Policlinico Umberto I Hospital, Sapienza University of Rome.
  • Orsi P; Anaesthesiology and Reanimation Unit, Department of Neurosciences, San Camillo-Forlanini Hospital, Rome.
  • Quartini A; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome.
  • Vitali M; ASUR Marche-AV4.
  • Ceccanti M; SITAC, Societa' Italiana per il Trattamento dell'Alcolismo, Rome.
  • Tirassa P; Institute of Biochemistry and Cell Biology, IBBC-CNR, Rome, Italy.
  • Fiore M; Institute of Biochemistry and Cell Biology, IBBC-CNR, Rome, Italy.
  • Iannitelli A; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila.
Clin Ter ; 171(1): e67-e74, 2021.
Article en En | MEDLINE | ID: mdl-33346332
BACKGROUND: Electroconvulsive Therapy (ECT) has been widely applied to treat schizophrenia (SCZ) in the presence of resistance to pharmacotherapy. The mechanism of action of ECT in schizophrenia has not been fully clarified, though its intrinsic mechanism presents analogies with some neurobiological processes mediated by nerve growth factor (NGF). OBJECTIVES: The aim of this study was to investigate in patients with treatment-resistant schizophrenia (TRS) the effect of ECT on acute and long-term NGF serum levels and the association with the clinical outcomes. METHODS: Twelve male inpatients with TRS underwent eight sessions of ECT. Blood samples were collected during the first and the eighth ECT at the following time points: 5 minutes before the induction of seizure and then at 0, 5, 15 and 30 minutes after seizure. RESULTS: Following ECT treatment, a substantial clinical improvement in symptom severity was indicated by a significant reduction in the Positive and Negative Syndrome Scale (PANSS) total and subscales scores. Even though the baseline NGF levels showed an increase over time, there were no statistical differences in NGF at time 0 at the first and the eighth ECT session. Furthermore, no correlation was observed between the severity of schizophrenic symptoms and NGF levels. CONCLUSIONS: This is the first study addressing peripheral NGF during ECT treatment in TRS, as well as the first study in which NGF has been evaluated in different ECT sessions at various time points. These findings may potentiate the knowledge about the neurotrophic effects of ECT and the role of NGF in synaptic plasticity related to possible mechanisms of schizophrenia treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquizofrenia / Factor de Crecimiento Nervioso / Terapia Electroconvulsiva Límite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Clin Ter Año: 2021 Tipo del documento: Article Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquizofrenia / Factor de Crecimiento Nervioso / Terapia Electroconvulsiva Límite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Clin Ter Año: 2021 Tipo del documento: Article Pais de publicación: Italia